On April 29, the Netherlands National Institute of Public Health and Environment, Radboud University and Erasmus Medical Center co-published a research paper entitled "Towards the Next Phase: Evaluation of Serological Assays for Diagnostics and Exposure Assessment" on medRxiv, a preprint service for health sciences. This research evaluated 11 novel coronavirus antibody detection reagents from China, Germany, USA and Italy and arrived at the result that the total antibody reagents (ELISA), co-developed by XMU and INNOVAX, exhibited optimal performance.

It is worth noting that INNOVAX’s serological reagents took the crown once more in the evaluation research of the leading authoritative institutions in European countries. Prior to this, Statens Serum Institut (SSI) conducted a comprehensive comparison of serological COVID-19 reagents from 9 countries, including China, Germany, USA and Canada, and found that the total antibody reagents (ELISA), co-developed by XMU and INNOVAX, outshone others in performance and efficacy. 

Source: School of Public Health